Prospective Follow-up and Pulmonary Functions From a Placebo-Controlled Randomized Trial of Ribavirin Therapy in Respiratory Syncytial Virus Bronchiolitis
Article Abstract:
There do not seem to be any adverse long-term effects in lung functions in the use of ribavirin for treating infants with respiratory syncytial virus and lower respiratory tract infection. There did not seem to be any increase in airway disease, in wheezing, or in pneumonia in the ribavirin group. Of 42 patients aged 1 to 33 months results seemed to favor the ribavirin group, and between ages 1 and 3 years the ribavirin group had significantly less airway disease, wheezing, and pneumonia in the placebo than the group which was not receiving it. The long-term beneficial effect of ribavirin therapy is promising, but larger numbers should be evaluated.
Publication Name: Archives of Pediatrics & Adolescent Medicine
Subject: Health
ISSN: 1072-4710
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Efficacy of bronchodilator therapy in bronchiolitis: a meta-analysis
Article Abstract:
Bronchodilating medication may improve symptoms in children with bronchiolitis. Bronchiolitis is a contagious lower respiratory tract infection marked by wheezing. Researchers reviewed the medical literature for studies on bronchodilators and bronchiolitis in children and found eight major studies of children with first-time wheezing. Bronchodilators provided temporary improvement in children with mild to moderately severe bronchiolitis. Bronchodilator treatment did not prevent children from being admitted to the hospital for further treatment. Although not all children respond to bronchodilators, treatment should be tried in all children.
Publication Name: Archives of Pediatrics & Adolescent Medicine
Subject: Health
ISSN: 1072-4710
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
Ribavirin for respiratory syncytial virus lower respiratory tract infection: a systematic overview
Article Abstract:
Ribavirin treatment may benefit infants with respiratory syncytial virus (RSV) pneumonia, but not enough patients have been studied to have confidence in those results. Researchers conducted a combined analysis of eight randomized controlled trials of ribavirin mist versus placebo. Ribavirin more than halved the death rate and the odds of respiratory deterioration, but not enough patients have been studied to be sure those results were not due to chance. Given that the drug alone costs $1,300 per day, further study is needed before recommending routine treatment of infants with RSV pneumonia.
Publication Name: Archives of Pediatrics & Adolescent Medicine
Subject: Health
ISSN: 1072-4710
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
- Abstracts: Obstructive sleep apnea. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema
- Abstracts: Mortality following inpatient addictions treatment: role of tobacco use in a community-based cohort. Prying Open the Door to the Tobacco Industry's Secrets About Nicotine
- Abstracts: Integration of behavioral and relaxation approaches into the treatment of chronic pain and insomnia. Cognitive behavioral therapy vs. zopiclone for treatment of chronic primary insomnia in older adults: A randomized controlled trial
- Abstracts: Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. Culmination of an era in research on the acute respiratory distress syndrome